Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02857270
Title A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Eli Lilly and Company
Indications

pancreatic ductal adenocarcinoma

Advanced Solid Tumor

melanoma

colorectal cancer

lung non-small cell carcinoma

Therapies

LY3214996

Gemcitabine + LY3214996 + Nab-paclitaxel

LY3214996 + Midazolam

Abemaciclib + LY3214996

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST